Keyphrases
Current Treatment
100%
Treatment Options
100%
Aspirin
100%
Bleeding Risk
100%
Emerging Treatments
100%
Antiplatelet Therapy
100%
Atherothrombotic Disease
100%
Oral Antiplatelet
100%
Thromboxane A2 (TXA2)
66%
Acute Coronary Syndrome
66%
Residual Risk
66%
Platelet Inhibition
66%
Ischemic Events
66%
Adenosine Diphosphate
66%
P2Y12 Inhibitors
66%
Peripheral Arterial Disease
33%
Vascular Disease
33%
Thrombosis
33%
Ischemic Stroke
33%
Inhibitory Effect
33%
Standard of Care
33%
Clinical Presentation
33%
Receptor Antagonist
33%
Clopidogrel
33%
Poor Clinical Outcomes
33%
Hemostasis
33%
Thrombus Formation
33%
Platelet Activation
33%
Genetic Components
33%
Platelet Aggregation
33%
Inter-patient Variability
33%
Novel Mechanism of Action
33%
Transient Ischemic Attack
33%
Thrombin
33%
Clinical Limitations
33%
Stroke Ischemic
33%
Protease-activated Receptor 1 (PAR1)
33%
Dual Antiplatelet Therapy
33%
Prasugrel
33%
Early Invasive Strategy
33%
Atherothrombotic
33%
Adenosine Diphosphate Receptors
33%
P2Y12
33%
Arterial Thrombus
33%
Platelet Agonists
33%
Platelet Activation Pathways
33%
Medicine and Dentistry
Emerging Treatment
100%
Antiplatelet
100%
Diseases
100%
Acetylsalicylic Acid
60%
Platelet
40%
Bleeding
40%
Acute Coronary Syndrome
40%
Thrombocyte Activation
40%
Thromboxane A2
40%
Adenosine Diphosphate
40%
Brain Ischemia
20%
Arteriosclerosis Obliterans
20%
Transient Ischemic Attack
20%
Blood Clotting
20%
Thrombosis
20%
Thrombocyte Aggregation
20%
Blood Stasis
20%
Artery Thrombosis
20%
Thrombin
20%
Proteinase Activated Receptor 1
20%
Prasugrel
20%
Platelet Agonist
20%
Adenosine Diphosphate Receptor Inhibitor
20%
Vascular Disease
20%
Clopidogrel
20%
Pharmacology, Toxicology and Pharmaceutical Science
Antiplatelet
100%
Diseases
100%
Acetylsalicylic Acid
60%
Adenosine Diphosphate
60%
Bleeding
40%
Acute Coronary Syndrome
40%
Thromboxane A2
40%
Clopidogrel
20%
Receptor
20%
Peripheral Occlusive Artery Disease
20%
Brain Ischemia
20%
Artery Thrombosis
20%
Transient Ischemic Attack
20%
Thrombin
20%
Prasugrel
20%
Proteinase Activated Receptor 1
20%
Thrombosis
20%
Vascular Disease
20%
Blood Stasis
20%